Targeting Sphingosine Kinase in AML

$220,672P01FY2013CANIH

Pennsylvania State Univ Hershey Med Ctr, Hershey PA

Investigators

Hong-Gang Wangcontact Mark Kester

Linked publications, trials & patents

Paper 39429505 Paper 39364061 Paper 38659944 Paper 38540794 Paper 38460719 Paper 38369184 Paper 38255815 Paper 38170742 Paper 38136410 Paper 37736793 Paper 37131653 Paper 36106439 Paper 36058252 Paper 35487785 Paper 35483419 Paper 35471732 Paper 35050458 Paper 34888943 Paper 34638385 Paper 34132194 Paper 33212155 Paper 33087509 Paper 32835586 Paper 32736077 Paper 32396937 Paper 32296637 Paper 32124438 Paper 31744877 Paper 31699964 Paper 31488436 Paper 31363040 Paper 31123028 Paper 31112736 Paper 31014364 Paper 30962310 Paper 30836822 Paper 30775933 Paper 30701264 Paper 30637412 Paper 30455079 Paper 30060815 Paper 29607443 Paper 29368980 Paper 29263930 Paper 29079707 Paper 28890935 Paper 28629373 Paper 28434262 Paper 28390927 Paper 28301528 Paper 28239612 Paper 28189725 Paper 28187452 Paper 27825124 Paper 27806293 Paper 27715403 Paper 27607576 Paper 27140664 Paper 26702062 Paper 26220867 Paper 26153136 Paper 26109102 Paper 25964209 Paper 25769964 Paper 25563902 Paper 25538041 Paper 25535900 Paper 25336151 Paper 24842334 Paper 24367685 Paper 23181473 Paper 21675727 Patent 11426371

Abstract

Little improvement in clinical outcomes has been achieved in acute myeloid leukemia (AML) patients over the past several decades. This is especially true for patients with

View original record on NIH RePORTER →